Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 4/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248433 | 0.82 | PIK3CA (0.44) | GCKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL248528 | 0.80 | GCK (0.46) | GCKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL248432 | 0.75 | PIK3CA (0.49) | GCKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL248192 | 0.74 | LRRK2 (0.39) | GCKPIK3CACDK9MTOR | |
| SCHEMBL248167 | 0.72 | PIK3CA (0.46) | PIK3CAPDE10AMTOR | |
| SCHEMBL248398 | 0.71 | DHFR (0.37) | PDE10ADYRK1A | |
| SCHEMBL24869132 | 0.67 | CDC7 (0.38) | GCKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL26162653 | 0.66 | CDC7 (0.36) | GCKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL30068220 | 0.65 | PIK3CA (0.40) | GCKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL26647381 | 0.65 | PIK3CA (0.40) | GCKPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | GCK 3916/4885PIK3CA 28/4885PIK3CD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.